Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.

…, C Viaplana, M Costa, E Felip-Falg's… - 2018 - ascopubs.org
3032 Background: HPD with ICIs has been recently described as progression disease (PD)
by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. …

[HTML][HTML] Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer

…, NE Ready, LQ Chow, EE Vokes, E Felip… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor
antibody, disrupts PD-1–mediated signaling and may restore antitumor immunity. …

[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

…, S Gadgeel, E Esteban, E Felip… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase …

E Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko… - The Lancet, 2021 - thelancet.com
Background Novel adjuvant strategies are needed to optimise outcomes after complete surgical
resection in patients with early-stage non-small-cell lung cancer (NSCLC). We aimed to …

Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer …

…, A Estival, RG Campelo, I Sullivan, E Felip… - 2022 - ascopubs.org
9010 Background: Atezolizumab plus chemotherapy was safe and yielded promising clinical
outcome as frontline therapy for patients (pts) with advanced NSCLC with untreated brain …

Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung.

…, F Salva, I Sansano, L Romero, E Felip… - 2014 - ascopubs.org
7569 Background: Recent clinical trials have shown that immune-checkpoint blockade can
result in striking and durable responses in advanced non-small cell lung cancer. Preliminary …

[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

…, R Stahel, S Peters, E Felip, R Stahel, E Felip… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second ESMO …

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia… - The Lancet, 2016 - thelancet.com
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer,
there remains a need for effective treatments for progressive disease. We assessed the …

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …

…, R Gervais, A Vergnenegre, B Massuti, E Felip… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …

…, J Menezes, E Richardet, J Bennouna, E Felip… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …